Literature DB >> 25192720

Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis.

Yue-Dong Wang1, He Chen, Hui-Qiag Liu, Min Hao.   

Abstract

The aim of this meta-analysis was to evaluate the clinical significance of serum osteopontin (OPN) levels in ovarian neoplasm in patients, with the goal of building a novel diagnostic score model. By searching the PubMed, Embase, Web of Science, Cochrane Library, CISCOM, CINAHL, Google Scholar, CBM, and China National Knowledge Infrastructure (CNKI) databases, we conducted a meta-analysis. Studies were pooled, and the standardized mean difference (SMD) and its corresponding 95 % confidence interval (CI) were calculated. Subgroup analyses and publication bias detection were also conducted. Version 12.0 STATA software was used for statistical analysis. We performed a final analysis of 1,653 subjects altogether (822 patients with psoriasis and 831 healthy controls) from 15 clinical case-control studies. The meta-analysis results showed a positive association between serum OPN levels and ovarian neoplasm (SMD = 2.60, 95 %CI 1.88-3.32, P < 0.001). The subgroup analysis by ethnicity detected that high levels of serum OPN may be the main risk factor for ovarian neoplasms in Asians (SMD = 2.91, 95 %CI 2.38-3.45, P < 0.001), but not in Caucasians (P > 0.05). The present meta-analysis indicated that serum OPN levels were generally elevated in ovarian neoplasm patients, and thus, serum levels of OPN could be useful in diagnosing ovarian neoplasm.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25192720     DOI: 10.1007/s13277-014-2314-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

Authors:  Norbert Avril; Stefanie Sassen; Barbara Schmalfeldt; Joerg Naehrig; Stephan Rutke; Wolfgang A Weber; Martin Werner; Henner Graeff; Markus Schwaiger; Walther Kuhn
Journal:  J Clin Oncol       Date:  2005-09-12       Impact factor: 44.544

2.  Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.

Authors:  Elisabetta Bandiera; Laura Zanotti; Aline S C Fabricio; Elisa Bucca; Elisa Squarcina; Chiara Romani; Renata Tassi; Eliana Bignotti; Paola Todeschini; Germana Tognon; Cesare Romagnolo; Massimo Gion; Enrico Sartori; Tiziano Maggino; Sergio Pecorelli; Antonella Ravaggi
Journal:  Clin Chem Lab Med       Date:  2013-09       Impact factor: 3.694

3.  MMP-7 as a prognostic marker in colorectal cancer.

Authors:  Selja Koskensalo; Johanna Louhimo; Stig Nordling; Jaana Hagström; Caj Haglund
Journal:  Tumour Biol       Date:  2010-08-28

4.  Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.

Authors:  Mitsuhiro Nakae; Ichiro Iwamoto; Toshinori Fujino; Yoshiyasu Maehata; Shin-ichi Togami; Mitsuhiro Yoshinaga; Tsutomu Douchi
Journal:  J Obstet Gynaecol Res       Date:  2006-06       Impact factor: 1.730

Review 5.  Osteopontin: role in immune regulation and stress responses.

Authors:  Kathryn X Wang; David T Denhardt
Journal:  Cytokine Growth Factor Rev       Date:  2008-10-25       Impact factor: 7.638

6.  Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation.

Authors:  Gang Song; Gaoliang Ouyang; Yubin Mao; Yanlin Ming; Shideng Bao; Tianhui Hu
Journal:  J Cell Mol Med       Date:  2009-08       Impact factor: 5.310

7.  Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta.

Authors:  Sylvia A Vetrone; Encarnacion Montecino-Rodriguez; Elena Kudryashova; Irina Kramerova; Eric P Hoffman; Scot D Liu; M Carrie Miceli; Melissa J Spencer
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

8.  Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway.

Authors:  Gang Song; Qiu-Feng Cai; Yu-Bin Mao; Yan-Lin Ming; Shi-Deng Bao; Gao-Liang Ouyang
Journal:  Cancer Sci       Date:  2008-10       Impact factor: 6.716

9.  LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma.

Authors:  Chih-kung Lin; Tai-Kuang Chao; Hung-Cheng Lai; Herng-Sheng Lee
Journal:  Am J Clin Pathol       Date:  2012-06       Impact factor: 2.493

10.  Test of ovarian cancer multiplex xMAP technology panel.

Authors:  Jindra Vrzalova; Marketa Prazakova; Zdenek Novotny; Ondrej Topolcan; Miroslava Casova; Lubos Holubec
Journal:  Anticancer Res       Date:  2009-02       Impact factor: 2.480

View more
  11 in total

1.  Clinical value of TV-CDS combined with serum tumor markers in diagnosis of ovarian cancer.

Authors:  Chunying Yu; Ting Dou; Yun Liu; Ruirong Liu
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

2.  Association of osteopontin polymorphism with cancer risk: a meta-analysis.

Authors:  Gang Yang; Xiaoxing Peng; Pengju Guo; Ge Yang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

3.  Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.

Authors:  Zhu Lan; Dan Fu; Xiuzhang Yu; Mingrong Xi
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

Review 4.  Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review.

Authors:  Zhi-De Hu; Ting-Ting Wei; Min Yang; Ning Ma; Qing-Qin Tang; Bao-Dong Qin; Hai-Tao Fu; Ren-Qian Zhong
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

5.  Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.

Authors:  Agnieszka Horala; Agata Swiatly; Jan Matysiak; Paulina Banach; Ewa Nowak-Markwitz; Zenon J Kokot
Journal:  Int J Mol Sci       Date:  2017-01-10       Impact factor: 5.923

6.  Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis.

Authors:  Cong Xu; Hua Li; Miao Yin; Tao Yang; Liguo An; Guiwen Yang
Journal:  Oncotarget       Date:  2017-10-12

7.  NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.

Authors:  Claudio Guarneri; Valentina Bevelacqua; Jerry Polesel; Luca Falzone; Patrizia S Cannavò; Demetrios A Spandidos; Grazia Malaponte; Massimo Libra
Journal:  Oncol Rep       Date:  2017-01-10       Impact factor: 3.906

Review 8.  The role of osteopontin in the progression of solid organ tumour.

Authors:  Hailin Zhao; Qian Chen; Azeem Alam; Jiang Cui; Ka Chun Suen; Aurelie Pac Soo; Shiori Eguchi; Jianteng Gu; Daqing Ma
Journal:  Cell Death Dis       Date:  2018-03-02       Impact factor: 8.469

9.  Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis.

Authors:  Dan Li; Wang Qian; Ruo Ran Li; Jinghao Zhang; K E Li; Yanmin Wu
Journal:  Biomed Rep       Date:  2016-02-29

Review 10.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.